{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T13:03:35Z","timestamp":1763125415485,"version":"3.45.0"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>\n                    A 66-year-old man with a pathology-confirmed gastric mucosa-associated lymphoid tissue (MALT) lymphoma underwent imaging with both\n                    <jats:sup>68<\/jats:sup>\n                    Ga-pentixafor and\n                    <jats:sup>18<\/jats:sup>\n                    F-FDG PET\/CT. The\n                    <jats:sup>18<\/jats:sup>\n                    F-FDG PET\/CT demonstrated intense FDG uptake in the gastric lesion, whereas the\n                    <jats:sup>68<\/jats:sup>\n                    Ga-pentixafor PET\/CT showed only minimal tracer uptake. Subsequent histopathologic evaluation confirmed a transformation into aggressive diffuse large B-cell lymphoma (DLBCL). This case underscores the importance of recognizing atypical imaging patterns to identify histologic transformation and guide timely clinical intervention.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000005957","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T17:11:05Z","timestamp":1747242665000},"page":"1181-1182","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["18F-FDG PET\/CT and 68Ga-Pentixafor PET\/CT Findings of Gastric Mucosa-associated Lymphoid Tissue Lymphoma Transformation to Diffuse Large B-cell Lymphoma"],"prefix":"10.1097","volume":"50","author":[{"given":"Zitong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hexiao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"R1-20251114","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1182\/blood.2021013239","article-title":"CXCR4 PET\/MRI for follow-up of gastric mucosa-associated lymphoid tissue lymphoma after first-line Helicobacter pylori eradication","volume":"139","author":"Mayerhoefer","year":"2022","journal-title":"Blood"},{"key":"R2-20251114","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00259-019-04605-z","article-title":"Chemokine receptor-4 targeted PET\/CT with (68)Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to (18)F-FDG PET\/CT","volume":"47","author":"Pan","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R3-20251114","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00259-023-06489-6","article-title":"Chemokine receptor-targeted PET\/CT provides superior diagnostic performance in newly diagnosed marginal zone lymphoma patients: a head-to-head comparison with [(18)F]FDG","volume":"51","author":"Kosmala","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R4-20251114","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00259-016-3518-y","article-title":"18F-FDG PET\/CT in gastric MALT lymphoma: a bicentric experience","volume":"44","author":"Albano","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R5-20251114","first-page":"153","article-title":"Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)","volume":"66","author":"Raderer","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"R6-20251114","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1093\/annonc\/mdv368","article-title":"Histologic transformation in marginal zone lymphomas\u2020","volume":"26","author":"Conconi","year":"2015","journal-title":"Ann Oncol"},{"key":"R7-20251114","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41408-023-00831-9","article-title":"Transformation and survival in marginal zone lymphoma: a Finnish nationwide population-based study","volume":"13","author":"Kalashnikov","year":"2023","journal-title":"Blood Cancer J"},{"key":"R8-20251114","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/annonc\/mdt507","article-title":"Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma","volume":"25","author":"Meyer","year":"2014","journal-title":"Ann Oncol"},{"key":"R9-20251114","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.imlet.2016.06.006","article-title":"CXCR4 signaling in health and disease","volume":"177","author":"Pozzobon","year":"2016","journal-title":"Immunol Lett"},{"key":"R10-20251114","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1097\/RLU.0000000000005426","article-title":"CXCR4-targeted PET imaging in hematologic malignancies: a systematic review and meta-analysis","volume":"50","author":"Chavoshi","year":"2025","journal-title":"Clin Nucl Med"},{"key":"R11-20251114","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/modpathol.2012.134","article-title":"Chemokine receptors in gastric MALT lymphoma: loss of CXCR4 and upregulation of CXCR7 is associated with progression to diffuse large B-cell lymphoma","volume":"26","author":"Deutsch","year":"2013","journal-title":"Mod Pathol"},{"key":"R12-20251114","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/RLU.0000000000005057","article-title":"MALT lymphoma in histologic transformation: FDG-avid but pentixafor-negative","volume":"49","author":"Tang","year":"2024","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005957","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T13:00:57Z","timestamp":1763125257000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":12,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005957","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"type":"print","value":"0363-9762"},{"type":"electronic","value":"1536-0229"}],"subject":[],"published":{"date-parts":[[2025,5,13]]},"assertion":[{"value":"2025-03-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}